IBI Lorenzini at the forefront against the counterfeiting of drugs
26 September 2017
Milan, 26 September 2017 – Tracing drugs through serial numbers to allow the identification of stolen or counterfeited products: IBI Lorenzini raises to the challenge to fight the pharmaceutical product counterfeiting market, one of the most serious threats to public health, and does it well in advance of the EU Regulation, which will enter into force in 2019, by implementing digital counter-measures for the reduction of risks. It’s the Rockwell Automation Pharma Suite software the electronic “key” that will guarantee safety, control and transparency for IBI products.
The pharmaceutical company of Aprilia, driven by Camilla Borghese Khevenhüller, at the forefront of the Industry 4.0 project, has introduced today in Milan, during an event dedicated to industrial automation (at the premises of Tecniche Nuove) the innovative strategies implemented in its production lines, giving particular attention to those relating to traceability, and the implementation of the Rockwell Automation software.
The whole European pharmaceutical sector will in fact soon have to accept the new challenge posed by EU Regulation 2011/62, which defines the drug control procedures for the reduction of counterfeiting threats. The new dispositions are part of a path initiated in 2013 by the USA market, when the then president Barack Obama signed the DSCSA (Drug Supply Chain Security Act). The achieving of these objectives requires the implementation of innovative electronic systems for the safe identification and tracking of drug prescription and distribution, and is the basis for the choice made by IBI.
“The track-and-trace” system”, explained during the event in Milan Luca Pezzano, Operational Director of IBI “greatly increases the safety of the drug production process. It guarantees in fact a higher level of transparency and responsibility in production, improves logistic exchanges and allows the identification of stolen and counterfeited products. The serial numbers are fundamental for managing the whole distribution process, ensuring complete traceability. For this reason”, he concludes “the serial number is printed on each sale unit, on each box containing single units and on each pallet where the boxes are stacked.”
The Industry 4.0 revolution is reaching all company sectors, and it was unavoidable that it would also affect such delicate fields for public health as the healthcare and pharmaceutical sectors. Total drug traceability is one of the main objectives of this digital revolution: for the USA market, the obligation for manufacturers starts from November 2017 and the project will be completed in 2023. On the other hand, as far as Europe its realisation should be completed by February 2019, while in Italy the limit is February 2025. IBI Lorenzini is therefore at the forefront in applying a change that in future years will be mandatory for all the companies of the sector.